Gene therapy with the Padua variant of a codon-optimised human factor IX gene etranacogene dezaparvovec in people with haemophilia B: Effects on patient-oriented outcomes measured using the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire in the HOPE-B study